Patients with acromegaly have a higher prevalence of vertebral fractures despite normal bone 17 mineral density (BMD), suggesting that GH overexpression has adverse effects on skeletal 18 architecture and strength. We used giant bovine GH (bGH) transgenic mice to analyze the effects of 19 high serum GH levels on BMD, architecture, and mechanical strength. Five-month-old hemizygous 20 male bGH mice were compared with age-and sex-matched nontransgenic littermates controls (NT; 21 n=16/group). Bone architecture and BMD were analyzed in tibia and lumbar vertebrae using 22
Introduction 36
GH is a peptide hormone secreted by the anterior pituitary gland, which has catabolic and 37 anabolic actions on many organ systems. In the skeleton, it facilitates linear bone growth by causing 38 chondrocyte proliferation at the epiphyseal cartilage in the growth plate region (1,-3) . GH also has 39 numerous metabolic functions regulating carbohydrate and lipid metabolism (4). It induces 40 intracellular signals through the GH receptor (GHR), a predimerized cytokine receptor signaling 41 through the Janus kinase (JAK)-signal transducer and activator of transcription pathway (STAT) (5). 42 Many of the growth-promoting actions of GH are mediated by IGF-1, which is synthesized in most 43 peripheral tissues, with liver synthesis contributing primarily to circulating IGF-1 levels (1). Both GH 44 and IGF-1 are anabolic hormones for the skeleton and are involved in the stimulation of bone 45
formation (1, 6 ). Although they have overlapping effects, GH and IGF-1 also have distinct effects on 46 skeletal development, bone growth, and fracture risk (7) . 47 The importance of GH in the regulation of bone growth is best seen in patients with GH 48 deficiency (GHD) or GH excess (8, 9). Patients with GHD have a low bone turnover, whereas excess 49 GH, usually due to a GH-secreting pituitary tumor causing acromegaly, is associated with increased 50 bone turnover (9, 10). Although patients with acromegaly have characteristically enlarged bones and 51 excess cortical bone and osteophytes, clinical reports and experimental studies have shown 52 inconsistent data on bone mineral density (BMD) and, paradoxically, a number of studies suggested 53 increased fracture risk in these patients (11,-16) . The clinical picture regarding bone is complicated 54 by the fact that patients with acromegaly often have hypogonadism due to excess prolactin 55 secretion and/or reduced gonadotropins due to tumor pressure effects. In active acromegaly, high 56 GH levels are associated with increased cortical BMD, whereas the effects on trabecular BMD are 57 more variable (17,-20) . In addition, fracture risk in acromegaly was shown to be either associated 58 with BMD or independent of it, suggesting that BMD alone is not a sufficient indicator of fracture 59 risk (12,-14, 21) . The effects of an excess GH on bone architecture and strength are still unclear. 60
Bone fracture risk is dependent on the overall bone strength, which itself depends on bone 61 structural and material properties, both of which are affected by bone turnover (22). Structural 62 properties of bone include its geometry and architecture (23), whereas its material properties 63 depend mainly on bone mineral and collagen contents that are affected by the rate of bone 64 remodeling (24) . 65
Several transgenic animal models have been developed to study the effects of GH on bone. 66
Transgenic expression of bovine GH (bGH) or rat GH in mice is now commonly used to study GH 67 physiology, and GH is often fused with a transcriptional regulatory element such as the 68
Bone histomorphometry 133
Tibia were fixed in 10% neutral-buffered formalin for 24 hours, dehydrated, and embedded 134 in methyl metacrylate at low temperature to preserve enzymatic activity (33 Committee nomenclature (35). L4 vertebrae preserved at 4° after micro-CT analysis were processed 146 in methyl metacrylate as described above and used to assess mineral and apposition rates. TRAP 147 staining was not possible in those vertebrae due to the loss of enzymatic activity. 148
PTH measurement 149
Serum PTH levels were measured using a commercial mouse PTH 1-84 ELISA kit (Immutopics). 150
Statistical analysis 151
The results were presented as mean ± SD. Comparisons between groups for all data were 152 performed using an unpaired t test (two tailed). Differences were considered significant at P < .05. 153
All statistical analyses were performed using GraphPad Prism Software (GraphPad Software Inc). 154
Linear regression analysis with adjustment for body weight was performed using SPSS. 155
156

Results
bGH mice have increased body weight and bone length compared with their littermate controls 158
Five-month-old hemizygous male bGH mice were compared with age-and sex-matched NT 159 controls (n = 16/group). As expected, bGH transgenic mice displayed significant increases in body 160 weight ( Figure 1A ). Bone lengths of tibia, femora, and lumbar vertebra (total length of L4 and L5) 161
were measured using micro-CT. All bones were consistently longer in bGH mice compared with NT 162 mice ( Figure 1, B-D Using micro-CT imaging, we found that the trabecular bone volume fraction (BV/TV) was 166 significantly reduced in the bGH mice compared with the NT mice, indicating that bGH mice have 167 low bone mass. This was the case when results were expressed both as direct measurements or 168 when they were adjusted for bone length differences between NT and bGH mice ( Table 1 ). The bone 169 structural analysis showed that the lower BV/TV was due to a reduction in both trabecular thickness 170 and number, although the reduction in trabecular thickness was more highly significant (Table 1) . 171
The significant decrease in BV/TV in bGH mice was confirmed by histomorphometry measurements 172 ( Cortical bone architecture was also analyzed at 37% and 50% of tibia length from its 179 proximal end. Similar data were obtained at both lengths, and Table 1 illustrates the results at 37% 180 of tibia length. Although cortical bone area was similar in bGH and NT mice, total cross-sectional 181 area, cortical bone perimeter, and medullary area were increased and cross-sectional thickness 182 significantly decreased in bGH mice compared with NT mice ( Table 1 ), suggesting that bone size and 183 geometry are different in bGH mice. All these differences remained highly significant after correction 184 for tibiae length. In contrast, only the decrease in cortical thickness in bGH mice remained significant 185 after adjustment for body weight. different in bGH and NT mice vertebrae, except when adjusted for bone length (Table 3) . Trabecular 194 thickness was significantly decreased in bGH vertebrae compared with the NT group, even after 195 adjustment for length and body weight, although histomorphometry data showed only a trend for a 196 decrease (Tables 3 and and4 ).4). Other trabecular parameters were not consistently affected. 197
Significant differences were also observed in cortical bone because L4 and L5 vertebrae in bGH 198 group showed increased bone cortical area but decreased cortical thickness (Table 3) To determine the cause of the low trabecular bone mass in bGH mice, we examined bone 208 cellular activities in the tibia of those mice, using bone histomorphometry. Histomorphometric 209 assessment confirmed our micro-CT findings that trabecular BV/TV in tibial metaphysis is 210 significantly decreased in bGH compared with NT mice ( Figure 4A and Table 2 ). Analysis of 211 mineralizing apposition and bone formation rates using double-fluorescence labeling showed that 212 bGH mice have a higher bone formation rate than NT mice ( Figure 4C ). MAR was significantly 213 increased ( Table 2 ). The percentage of TRAP-positive surfaces (representing resorption surfaces) was 214 also significantly higher in the bGH mice compared with NT mice ( Figure 4B ). These results indicate 215 that the bGH mice have a higher trabecular bone turnover compared with their littermates controls, 216 which is associated with a low trabecular bone mass phenotype. The increased bone formation rate 217 in bGH mice compared with their littermate controls was also observed in vertebrae (Table 4) . We 218 also measured serum PTH levels in our mice, and we found significantly increased PTH levels in 5-219 month-old male bGH mice compared with littermate controls ( Figure 4D) . 220
221
Discussion 222
This study shows that bGH mice with elevated serum GH levels have compromised bone 223 architecture, characteristic that often mimics the skeletal changes experienced by acromegaly 224 patients. The use of bGH mice is a valuable model for the study of skeletal changes in response to 225 excess GH that occur in acromegaly patients. The advantage of this experimental mouse model is 226 that there is no associated hypogonadism (36), so it is easier to decipher the skeletal effects of 227 excess GH than in acromegaly patients. There is, however, a major difference between the bGH 228 mouse model and acromegaly patients as in patients' overexpression of GH usually occurs after 229 epiphyseal closure. Conversely, overexpression of GH in bGH mice occurs in utero and through adult 230 life. Thus, it is possible that the temporal control of GH overexpression has implications on bone 231
regulation. 232
Our works shows that bGH mice have significant increases in total body weight and in bone 233 lengths. This supports previous studies that demonstrated that human GH and bGH transgenic mice 234 are larger and exhibit disproportionate skeletal gigantism (28,-30, 37, 38). Bone sizes are increased 235 in bGH mice (30) , and treatment of growing rats with human GH rats leads to an increase in bone 236 size (39). Elevated levels of GH appear to be the main cause for gigantism in those mice rather than 237 an increase in mechanical loading as a result of increased body weight (40). 238
Bone architecture in bGH mice has been poorly studied. GH has complex effects on bone 239 that vary, depending on the skeletal compartments and different sites. Using high-resolution micro-240 CT, we found that bGH mice have altered cortical and trabecular bone architecture in long bones. was also significantly decreased in tibia despite increases in total cross-sectional area, cortical tissue 249 perimeter, and medullary area, reflecting the bigger tibia in bGH mice. Previous micro-CT analysis of 250 GH transgenic mice did not show any major change in trabecular bone volume fraction in male mice. 251
In contrast, female transgenic mice showed an increase in trabecular bone fraction volume in 252 femora (29). This discrepancy could be due to a different mouse genetic background and/or the age 253 of the mice because the transgenic mice used in our study are older (5 mo vs 3 mo in the previous 254 study). Our resolution for micro-CT analysis of bone architecture was also 10 times higher than that 255 used in the former study (29) . 256
Because there is an increased prevalence of vertebral fractures in acromegaly patients (12) , 257
we also examined bone architecture and BMD in vertebrae of bGH mice. Surprisingly, there were no 258 significant changes in trabecular BMD and bone volume fraction in L4 and L5 vertebrae of bGH mice 259 compared with controls but a decrease in trabecular thickness. Cortical bone was more significantly 260 affected because bGH mice have significantly lower cortical BMD and cortical thickness in the lumbar 261 vertebrae than their controls. Although cortical bone density was also previously shown to be 262 significantly lower in femora of bGH transgenic mice (30), these results in mouse models conflict 263 with clinical records whereby elevated GH levels are often linked to increased cortical BMD in 264 humans (1, 19, 20, 42) . Clinical data are, however, mostly based on BMD measurements by dual-265 energy X-ray absorptiometry, which cannot discriminate between cortical and trabecular 266 compartments, in contrast to micro-CT or peripheral quantitative computed tomography (pQCT). 267
The view of increased cortical BMD in patients with active acromegaly is supported by the fact that 268 these patients have an increase in BMD at the forearm and/or femoral neck, two sites at which 269 cortical bone is the main determinant of bone strength, whereas BMD is less affected at the lumbar 270 spine, a site at which trabecular bone is dominant (19, 43, 44 ). This was corroborated in a clinical 271 study using high-resolution pQCT, which showed higher cortical density in the distal tibia in patients 272 with active acromegaly compared with controlled acromegaly (20), suggesting that high resolution 273 pQCT should allow better in vivo assessments of the bone architecture in acromegaly patients in the 274
future. 275
Interestingly, studies conducted in childhood-and adult-onset GHD have also shown 276 reduced cortical bone (45) and GH therapy in GHD patients seems to have a greater effect on cortical 277 than on trabecular bone (46). Our data support previous conclusions demonstrating that the skeletal 278 effects of GH depend on the compartment and the site analyzed, and this may be due to changes in 279 vascular supply, response to sex steroids, and/or mechanical loading (19). We used only males in our 280 study to restrict the differences in cortical density between sexes. We analyzed bone architecture at 281 two sites with a very different ratio in cortical and trabecular bone but that are also subject to 282 different loading environments. We therefore cannot exclude that the differences in bone 283 architecture between bGH mice tibiae and vertebrae depend on mechanical sensitivity to loading, 284 which is essential for the maintenance of the skeleton in both humans and animals. Previous studies 285 have shown that the GH/IGF-1 signaling pathway is regulated by in vivo mechanical loading (47) . 286
At all sites examined, our data suggest a deterioration of bone architecture. This was 287 confirmed by the decreased intrinsic material properties of femora of bGH mice, leading to a 288 reduction in bone strength, which may explain the higher rate of fractures in acromegaly patients. 289
Decreased trabecular bone biomechanical competence was also observed in acromegaly patients 290 (48) . Interestingly, it was shown that local production of human GH in osteoblasts in a model of 291 transgenic mice induces bone growth as expected but impaired the bones mechanical properties 292 (49). In contrast, erythroid-specific expression of human GH leads to bones with high bone density 293 and increased biomechanical properties (50) . This suggests that localized GH expression could have 294 opposing effect to global GH expression as observed in our study. In models of GHD, bone 295 mechanical properties are also not always rescued with GH treatment (51). It is, however, puzzling 296 that acromegalic patients have a higher prevalence of vertebral fractures because our data suggest 297 that trabecular architecture in bGH vertebrae is less deteriorated than in tibiae. 298
The cortex also contributes to a significant part of vertebral bone strength (52) and other 299 bone quality parameters, such as collagen content, and morphology may play a role. It is also 300 important to point out that the spine in the mouse is not a good model of the spine in humans 301 because it has almost no load bearing. Bone strength depends on bone morphology and composition 302 that can be associated with changes in bone turnover rate. Our results indicate that bone turnover is 303 largely increased in the trabecular bone of adult bGH mice tibia. We also found an increase in the 304 number of mineralizing surfaces and osteoclasts on bone surfaces, suggesting that bone cell 305 numbers and activities are both stimulated in bGH mice compared with controls. To our knowledge, 306 this is the first demonstration of accelerated bone turnover in favor of bone resorption in the 307 skeleton of bGH mice, and this may explain the deterioration of bone mechanical strength in these 308 mice. Bone turnover markers in acromegaly patients are also increased (19) and GH treatment is 309 effective in enhancing bone turnover (46, 53, 54). The increased bone turnover in bGH mice suggests 310 that the deterioration of bone architecture observed in those mice is not the consequence of 311 changes occurring during bone development that can affect bone architecture later in life. The 312 increase in cortical perimeter together with the decrease in cortical thickness observed in bGH mice 313 suggest that endosteal bone resorption and periosteal bone formation are both enhanced, which 314 explains the increase in bone size. Interestingly, we found a similar increased bone formation rate in 315 the vertebral trabecular bone of bGH mice compared with controls, suggesting that bone cellular 316 activities are also stimulated in vertebrae, although this needs to be confirmed in case of osteoclast 317 activity. 318
The mechanisms leading to the enhanced bone turnover in bGH mice whose net balance is 319 bone resorption is yet unclear. Our data show increased PTH levels in bGH mice, which could 320 contribute to this greater bone turnover (55) . GH transgenic mice have also hyperinsulinemia 321 despite euglycemia (56). Other possible mechanisms include stimulation by GH and IGF-1 of 322 proinflammatory cytokines that may promote osteoclastogenesis (57) . A very exciting future aspect 323 of this work will be to determine which direct or indirect signaling pathways link the excess GH in 324 our mouse model to these deleterious effects on bone. GHR affects many signaling pathways, the 325 major one being the JAK/STAT but additional independent pathways have been identified (58) . 326
Among the pathways affected by GHR activation and JAK2 are the MAPK and phosphatidylinositol 3-327 kinase/Akt pathways, which play crucial roles in the differentiation, function, and survival of bone 328 cells (59) . GH also regulates IGF-1 expression that has direct effects on bone via IGF-1 receptor and 329 downstream signaling cascades critical for bone cell survival and metabolism (60). It is also possible 330 that in our mouse model, the high GH tone may lead to feedback inhibition. Recent studies have 331 indicated that GHR activation induces suppression of cytokine signaling (SOCS) proteins, which in 332 turn inhibit GH signaling through a negative feedback mechanism. SOCS play important roles in 333 skeletal development and osteoclastogenesis (61) . 334
In conclusion, our data collectively indicate that elevated serum GH levels have negative 335 effects on bone architecture and quality in male mice. Combining, for the first time, high-resolution 336 micro-CT measurements of skeletal architecture in trabecular and cortical compartments, bone 337 mechanical testing, and quantification of bone cellular activities, we show that bGH mice display 338 characteristics of the skeletal changes observed in acromegaly patients, which vary according to the 339 skeletal site. Our study is limited by the fact that we have only analyzed males and only at one 340 particular time point; therefore, we cannot exclude that bGH female mice may behave differently 341 because the skeletal effects of GH may be influenced by sex steroids and mechanical loading. It, 342 however, supports the notion that bone strength is decreased in acromegaly patients and that this 343 may not always be reflected in the measurement of BMD. The inability of BMD to predict fracture 344 risk in acromegaly patients is also true in diabetic patients (62) Biomechanical properties of the excised mouse femurs in NT and bGH mice aged 5 months using the 590 three-point bending test, which tested for ultimate stress (A), Young's modulus (B), and stiffness (C). 591
Bars represent mean ± SD of six mice per group. *, P < .05, **, P < .001 NT vs bGH mice. 
